Averna Therapeutics

Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA

Health Tech & Life Sciences
Active
Series A Ness Ziona, Israel Founded 2022
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$82.0M
Last: 2024-06
Stage
Series A
Founded
2022
Headcount
51
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Averna Therapeutics is a biotechnology company specializing in the development of genomic medicines aimed at treating a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's proprietary technology focuses on inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome. These regions are selected to allow stable gene integration without disrupting normal cellular functions. By encoding their medicines in RNA, Averna utilizes validated, non-viral delivery platforms that are designed to be safe, efficient, scalable, and cost-effective. This approach also permits redosing with the intent to achieve curative outcomes.

Funding history · 1 round · $82.0M total

2024-06

Q&A

What is Averna Therapeutics' primary focus?
Averna Therapeutics specializes in genomic medicines, developing treatments for genetic disorders, cancer, and autoimmune conditions by inserting therapeutic genes into safe harbor regions of the DNA.
When was Averna Therapeutics founded?
Averna Therapeutics was founded in January 2022.
Where is Averna Therapeutics headquartered?
Averna Therapeutics is headquartered in Ness Ziona, Center District, Israel.
How many employees does Averna Therapeutics have?
Averna Therapeutics has 51-200 employees.
What is Averna Therapeutics' total funding to date?
Averna Therapeutics has raised a total of $82,000,000 USD.
When did Averna Therapeutics complete its last funding round and who were the lead investors?
In June 2024, Averna Therapeutics completed a funding round of $82,000,000 USD, with.
What is Averna Therapeutics' current funding stage?
Averna Therapeutics is currently in its Series A funding stage.
What is Averna Therapeutics' primary sector?
Averna Therapeutics' primary sector is Health Tech & Life Sciences.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2C

Tags

pharmaceuticalshealthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)